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Abstract
This review describes the preparation of core-corona type polymeric nanoparticles and their applications in various technological and
biomedical fields. Over the past two decades, we have studied the synthesis and clinical applications of core-corona polymeric nanoparticles
composed of hydrophobic polystyrene and hydrophilic macromonomers. These nanoparticles were utilized as catalyst carriers, carriers for
oral peptide delivery, virus capture agents, and vaccine carriers, and so on. Moreover, based on this research, we attempted to develop novel
biodegradable nanoparticles composed of hydrophobic poly(g-glutamic acid) (g-PGA) derivatives (g-hPGA). Various model proteins were
efficiently entrapped on/into the nanoparticles under different conditions: encapsulation, covalent immobilization, and physical adsorption.
The encapsulation method showed the most promising results for protein loading. It is expected that biodegradable g-hPGA nanoparticles
can encapsulate and immobilize various biomacromolecules. Nanoparticles consisting of hydrophobic and hydrophilic segments have great
potential as multifunctional carriers for pharmaceutical and biomedical applications, such as drug, protein, peptide or DNA delivery systems.
 2007 Elsevier Ltd.
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Open access under CC BY-NC-ND license.1. Introduction
Nanoparticles prepared from synthetic or natural polymers
have applications in various technological and biomedical
fields, because their chemical structures, surface functional-
ities, and particle size can be easily controlled. Nanoparticles
can be defined as colloidal systems with a diameter smaller
than 1000 nm [1,2]. Several methods have been developed
for preparing nanoparticles. These methods can be divided
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tion requires a polymerization reaction or can be synthesized
directly from a systemic prepared or natural polymer [3].
Nanoparticles with entrapped therapeutic agents, such as small
molecules, peptides, proteins and DNA, have recently been
shown to possess significant potential as drug delivery systems
and adjuvants [4e8]. A colloidal delivery system is one of the
most promising because it may reduce unwanted toxic side
effects and improve the therapeutic effect. These delivery
systems include nanoparticles, liposomes, microemulsions,
polymeric self-assemblies, and so on.
Recently, self-assembling block copolymers or hydrophobi-
cally modified polymers have been extensively investigated in
the field of biotechnology and pharmaceuticals. Amphiphilic
6730 T. Akagi et al. / Polymer 48 (2007) 6729e6747block or graft copolymers form self-assembled, nano-sized
micelle-like aggregates of various morphologies in aqueous
solution [9,10]. In general, self-assembled nanoparticles are
composed of an inner hydrophobic core and an outer shell
of hydrophilic groups. Hydrophobic blocks form the inner
core of the structure, which act as a drug incorporation site,
especially for hydrophobic drugs. Hydrophobic drugs can
thus be easily entrapped within the inner core by hydrophobic
interactions. These self-aggregating characteristics of the
polymers have attracted considerable attention as effective tar-
getable drug carriers, for example polyion complex micelles
[11] and hydrophobized polysaccharides. Among the different
carriers for controlled drug delivery, there has been rising in-
terest in nano-sized self-aggregates composed of natural poly-
saccharides, such as pullulan [12,13], curdlan [14], dextran
[15], alginic acid [16] and chitosan [17]. It was reported that
self-aggregated hydrogel nanoparticles could be formed from
cholesterol-bearing pullulan by an intra- and/or intermolecular
association in diluted aqueous solution [18].
Over the past two decades, we have developed a synthetic
method for polymeric nanoparticles based on the free radical
copolymerization of hydrophilic macromonomers, which are
vinylbenzyl group-terminated water-soluble polyvinyl com-
pounds, with hydrophobic monomers (styrene and methyl
methacrylate) in polar organic solvents [19]. During polymer-
ization, amphiphilic graft polymers assemble in solution to
form core-corona type nanoparticles, which have hydrophobic
cores and hydrophilic corona layers on their surfaces, resulting
in an excellent aqueous dispersion [20]. Moreover, our group
recently developed novel biodegradable nanoparticles com-
posed of hydrophobically modified poly(g-glutamic acid)
(g-PGA) prepared by the covalent attachment of L-phenylalanine
ethylester (L-PAE). This amphiphilic g-PGA formed monodis-
persed nanoparticles or nanofibers in water and the nanopar-
ticles did not induce any cytotoxicity [21,22]. We have also
reported nanoparticles comprised of poly(3-lysine) bearing
cholesterol [23].
In this review, we summarize the preparation of core-
corona type polymeric nanoparticles and their biomedical
applications. Furthermore, we describe the potential of self-
assembled nanoparticles composed of g-PGA hydrophobic
derivatives (g-hPGA) developed by our research group as
protein carriers.
2. Preparation of polymeric nanoparticles
2.1. Particle preparation processes
Conventionally, polymeric nanoparticles have been pre-
pared mainly by two methods: (i) the polymerization and poly-
condensation of monomers, and (ii) the dispersion of
preformed polymers [1]. Polymerization methods can be dis-
tinguished as: emulsion, dispersion and suspension polymeri-
zation, according to the solubility of the monomer and
polymer in the dispersion medium. Emulsion polymerization
has been extensively studied as a method for preparing nano-
particles [3,24]. This approach is one of the fastest methodsfor nanoparticle preparation and is readily scalable. Briefly,
the hydrophobic monomer is dispersed as emulsion in an aque-
ous phase, the radical polymerization is initiated in the aque-
ous phase, polymer particles are nucleated and grow by means
of a flux of new monomer from the monomer emulsion drop-
lets. The polymerization course and the final size of the parti-
cles are controlled by the addition of the chemical initiator or
by the variations in physical parameters with or without the
presence of surfactants to stabilize the particles. Particle for-
mation by emulsion polymerization has been primarily devel-
oped for the radical polymerization of vinyl monomers such as
styrene, acrylates or methacrylates [25].
On the other hand, several methods have been reported to
prepare biodegradable nanoparticles from poly(lactic acid)
(PLA), poly(lactide-co-glycolide) (PLGA), and poly(3-capro-
lactone) (PCL) by dispersing preformed polymers [1,4]. In
this method, solvent evaporation is a common and convenient
method for nanoparticle preparation. The polymer is dissolved
in an organic solvent like dichloromethane, chloroform or
ethyl acetate, and then emulsified into an aqueous solution
to create an oil-in-water (o/w) emulsion by using a surfactant
such as poly(vinyl alcohol). After the formation of a stable
emulsion, the organic solvent is evaporated by increasing the
temperature under pressure. The effect of this process is vari-
able depending on the properties of the nanoparticles.
Amphiphilic block or graft copolymers consisting of hydro-
philic and hydrophobic segments are self-assembling mate-
rials, and are capable of forming polymeric associates in
aqueous solutions. These nanoparticles can be prepared by sol-
vent displacement or direct dispersion method of amphiphilic
polymers [18]. Solvent displacement method is based on the
precipitation of a dissolved polymer from organic solution
and the diffusion of the organic solvent in the aqueous
medium. Generally, amphiphilic polymers dissolved water-
miscible organic solvents were dialyzed against water to
form nanoparticles. Aggregates of various morphologies
have been observed in a number of self-assembled polymeric
systems. The morphology of the nanoparticles produced from
amphiphilic block/graft copolymers can be varied by changing
the composition of the hydrophobic and hydrophilic blocks on
the polymer chains [26e28]. Amphiphilic block copolymers,
such as poly(ethylene glycol)-b-poly(lactic acid) (PEG-b-
PLA) or PEG-b-PCL, are very attractive for use as drug deliv-
ery applications [29,30].
2.2. Preparation of core-corona type polymeric
nanoparticles
In our research group, polymeric nanoparticles with hydro-
phobic polymer cores and hydrophilic polymer coronas have
been simply synthesized by the free radical copolymerization
of hydrophilic macromonomers and hydrophobic comonomers
in a polar solvent such as alcohol or a water/alcohol mixture
[31e48]. The mechanism of nanoparticle formation is shown
in Fig. 1. During the polymerization of hydrophilic macromo-
nomers with hydrophobic comonomers in a polar solvent in
the presence of a radical initiator, the generated amphiphilic
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Fig. 1. Mechanism of core-corona type polymeric nanoparticle formation.copolymers self-assembled in order to form core-corona poly-
meric nanoparticles, possibly with a hydrophobic core and
a hydrophilic graft polymer layer on their surfaces (Fig. 2).
Electron spectroscopy for chemical analysis (ESCA), dynamic
light scattering (DLS) measurement, and transmission electron
microscope (TEM) observations supported the accumulation
of a macromonomer component on the surface of the nanopar-
ticles [39,40,46,48]. The size of the nanoparticles, the molec-
ular weight of the graft polymers, and the conversion of
polymerization increased with an increase in the reaction
time, thus indicating an in situ self-assembling process for
nanoparticle formation. When PEG macromonomers and
methyl methacrylate (MMA) are used as hydrophilic macro-
monomers and hydrophobic comonomers in water/ethanol
mixture, first methacrylate-rich graft copolymers are produced
to form a nucleus of the particles, and then MMA is adsorbedin particles similar to dispersion polymerization. PEG branches
act as a stabilizer to form stable nanoparticles. Moreover, MMA
is easy to come into hydrophobic domain of the particles and
propagate. Propagation polymer radicals in the particles are
considered to be stable and have a long lifetime. Also, the ter-
mination rate of the radicals decreases in the particles, as the
viscosity of the polymerization medium increases. Conse-
quently, molecular weight of graft copolymers can be assumed
to increase in the last stage of copolymerization [20,31]. Other
research groups have also synthesized similar core-corona
nanoparticles using the same methodology [49e51].
Their size distributions were also quite narrow and uniform
in all cases. The size of the nanoparticles (100 nm to 3 mm)
could be controlled by changing the polymerization conditions
[43,44]. By designing and synthesizing different functional
macromonomers, a variety of water-dispersible nanoparticlesHydrophobic
core
Hydrophilic
corona
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Fig. 2. (a) Structure of core-corona type polymeric nanoparticles. (b) TEM images of nanoparticles.
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obtained. For instance, we have already developed nanopar-
ticles bearing pH sensitive anionic poly(methacrylic acid)
(PMAA) [37], cationic poly(vinylamine) (PVAm) [52], non-
ionic poly(ethylene glycol) (PEG) [44], thermosensitive
poly(N-isopropylacrylamide) (PNIPAAm) [39] and poly(N-
vinylisobutyramide) (PNVIBA) [42]. Regulating the monomers
used and the reaction conditions can easily control their sur-
face properties, such as the density or molecular weight of
their hydrophilic polymers, the charge or its distribution, and
the stimuli responses.
3. Application of core-corona type polystyrene
nanoparticles
Core-corona nanoparticles have highly hydrated polymer
coronas in the aqueous phase. The surface functionalities (neu-
tral, cationic, anionic, thermoresponsive units) of core-corona
nanoparticles can be readily modified by changing the macro-
monomer. To investigate their potential functions, we have
prepared the nanoparticles conjugated with proteins [53], pep-
tides [54], saccharides [55,56], and metal particles [57e62]
using functional groups introduced onto the corona. Fig. 3
shows an example of the application of these core-corona
nanoparticles.
3.1. Oral peptide delivery by nanoparticles
Nanoparticles have been studied extensively as carriers for
oral peptide delivery [63e65]. We evaluated the usefulness of
core-corona nanoparticles as carriers for hydrophilic peptide
drugs, and their potential as carriers that enhance peptide ab-
sorption via the gastrointestinal (GI) tract. Salmon calcitonin
(sCT) was used as a model drug to study the oral delivery
of peptides, and it is well known that its absorption can be
evaluated from the hypocalcemic effect which is only found
in the intact form [66].After the oral administration of mixtures of sCT and nano-
particles to rats, the ionized calcium concentration in the blood
obtained from the tail vein was measured. The blood ionized
calcium concentration decreased slightly after the oral admin-
istration of sCT aqueous solution (Fig. 4). This result suggests
that a small amount of intact sCT is absorbed via the GI tract,
although the majority is degraded by proteases, and the mem-
brane permeability of the residual intact sCT is very low. We
found that sCT absorption via the GI tract is enhanced by the
nanoparticles, and that this enhancement was affected by the
chemical structure of the macromonomers on the nanoparticle
surface. sCT absorption was enhanced most strongly by nano-
particles with PNIPAAm chains on their surfaces (Fig. 4) [67].
PNVA and PEG nanoparticles did not show this enhancement
effect on sCT absorption. The absorption of sCT was also en-
hanced by nanoparticles with surface PMAA or PVAm chains,
although the enhancement was weaker than that induced by
the PNIPAAm nanoparticles (data not shown).
The hypocalcemic effects after oral administration of mix-
tures of sCT and nanoparticles were only retained for 4 h, irre-
spective of the macromonomer structure. This suggests that
the absorption amount of sCT was not sufficient for inducing
the substantial hypocalcemic effect. We found two ways to im-
prove further this low absorption of sCT. One way is to opti-
mize the administration schedule of the mixture of sCT and
PNIPAAm nanoparticles [68]. When the dose of the mixture
was halved and one half was given orally 40 min after the
other half, the sCT-induced hypocalcemic effect was markedly
enhanced by PNIPAAm nanoparticles. The area of the reduc-
tion in the blood ionized calcium concentration was about
three times that after administration of a single full dose of
the same mixture.
The other way to improve sCT absorption is to optimize the
chemical structure of the nanoparticles. When styrene was po-
lymerized with two different kinds of macromonomers, poly-
styrene nanoparticles having two macromonomer chains on
their surfaces were obtained [69]. The enhancement effect ofOral peptide deliveryCatalyst carrier
Metal ion
Assembled material
Immunodiagnostic
agent 
Virus capture
Virus
Vaccine carrier
Dendritic cells
Fig. 3. Applications of core-corona type polymeric nanoparticles.
6733T. Akagi et al. / Polymer 48 (2007) 6729e6747sCT absorption by PNIPAAm nanoparticles was increased
considerably by introducing cationic PVAm chains to their
surfaces. The area of the reduction in the blood ionized cal-
cium concentration was increased by about three-fold. On
the other hand, the introduction of nonionic PNVA chains
eliminated completely the absorption-enhancing function of
PNIPAAm nanoparticles. It has been confirmed that nanopar-
ticles having surface PNVA and PMAA chains have no charge,
irrespective of the ratio of anionic PMAA chains. PNVA
chains probably shield the other functional groups on the
same nanoparticle surface. It seems that this shield prevented
the PNIPAAm groups from enhancing sCT absorption.
3.2. Mechanism of peptide delivery by nanoparticles
It has been reported that mucoadhesive polymers improve
the bioavailability of poor absorptive drugs [70]. We have ex-
amined the mechanism of the enhancement effect of sCT ab-
sorption by these nanoparticles in detail and proved that the
absorption enhancement results mainly from both mucoadhe-
sion of nanoparticles incorporating sCT in the GI tract and
an increase in the stability of sCT against degradation by
digestive enzymes [71e73].
The GI transit time of each radiolabeled type of nanopar-
ticles in rats indicated that PNIPAAm, PVAm and PMAA
nanoparticles adhered to the GI mucosa, and that PNVA nano-
particles did not have the mucoadhesive property. The mu-
coadhesive strength of PNIPAAm nanoparticles was stronger
than those of PVAm and PMAA nanoparticles in the in situ
experiments. The mucoadhesive property of nanoparticles
appears to be related to the absorption enhancement of orally
administered sCT because there was a good correlation
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Fig. 4. Concentrationetime profiles of ionized blood calcium levels after the
oral administration of sCT aqueous solution, a mixture of sCT and NVA nano-
particles, a mixture of sCT and PEG nanoparticles, and a mixture of sCT and
PNIPAAm nanoparticles in rats (0.25 mg sCT/2.5 ml dosing solution/kg rat).
The nanoparticle concentration in the dosing solution was 10 mg/ml. The PNI-
PAAm nanoparticle size and molecular weight of the macromonomers were
750 nm and 3500, respectively. Each value represents the means SE. Data
from Ref. [67].between the strength of mucoadhesion and the effect of the
in vivo absorption enhancement [71]. On the other hand, nano-
particles protected sCT against digestive enzyme-catalyzed
degradation in an in vitro study. This stabilizing effect was af-
fected by the chemical structure of the hydrophilic polymeric
chains on the nanoparticle surface. There was a good correla-
tion between the in vitro stability of sCT in the presence of
nanoparticles and the ranking of the in vivo effectiveness of
nanoparticles for enhancing the absorption of sCT [72]. It
was concluded that the absorption enhancement of sCT by
nanoparticles resulted from both the mucoadhesion of nano-
particles incorporating sCT onto the intestinal mucosa, and
an increase in the stability of sCT against digestive enzymes.
3.3. Immobilization of proteins onto the nanoparticles
Polymeric micro/nanoparticles have an extremely large
specific surface, and are frequently used for the immobiliza-
tion of biomolecules such as antibodies and enzymes in order
to create immunoassays [74] and catalytic systems [58]. En-
zymes are immobilized onto or into the particles to increase
their thermostability, operational satiability, and recovery [75].
Core-corona nanoparticles have highly hydrated polymer
coronas with functional groups in the aqueous phase, allowing
the covalent conjugation of biomolecules such as proteins.
Thus, we investigated the immobilization of lectins onto
PMAA-covered polystyrene nanoparticles, and their capture
of human immunodeficiency virus type 1 (HIV-1) through af-
finity interaction between the gp120 mannose and the immobi-
lized lectins. The mean diameters of the nanoparticles used
were 310, 360, 660, 940, and 1230 nm. Nanoparticles of dif-
ferent sizes showed a strongly negative zeta potential
(35 mV) in phosphate-buffered saline (PBS). This could be
attributed to the presence of ionized carboxyl groups from
the graft chains on the nanoparticle surfaces.
Concanavalin A (Con A) was also covalently immobilized
to the nanoparticles (Fig. 5a). The carboxyl groups of the
nanoparticle surface were first activated by 1-ethyl-3-(3-
dimethyl aminopropyl) carbodiimide (WSC) and were mixed
with Con A in PBS. Con Awas immobilized onto the nanopar-
ticles by amide bonds between carboxyl groups on the nano-
particle surfaces and Con A amide groups. Fig. 5b and c
shows the amount of Con A immobilized onto nanoparticles
of different sizes by covalent binding [76]. The amount of im-
mobilized Con A increased upon increasing the concentration
of Con A. The efficiency of Con A immobilization using WSC
reached about 50% at maximum. The amount of Con A immo-
bilized per nanoparticle unit weight showed a different ten-
dency based on the size of the nanoparticles (Fig. 5b); the
amount of covalently immobilized Con A increased upon de-
creasing the size of the nanoparticles. These differences can be
attributed to the surface area per unit weight of the nanopar-
ticles. The surface area of the nanoparticles per milligram
was 159, 87, 61, and 47 cm2 for the 360, 660, 940, and
1230 nm sized nanoparticles, respectively. The amount of
Con A immobilized per unit surface area (cm2) did not differ
significantly according to the size of the nanoparticles
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Fig. 5. Immobilization of concanavalin A (Con A) onto the surface of nanoparticles (a). Effect of the particle size on the amount of Con A immobilized onto
nanoparticles (NP). NP were treated with WSC and Con Awas mixed to a final concentration of 0.25e2 mg/ml. The amount of immobilized Con Awas calculated
by the immobilized Con A weight (mg)/NP weight (1 mg) (b), and the immobilized Con A weight (mg)/surface area of NP (cm2) (c). Data from Ref. [76].(Fig. 5c) [76]. These results demonstrate that the amount of
immobilized Con Awas significantly dependent on the surface
area of the particle. Nano-sized particles appeared to be more
effective for loading proteins when compared to micro-sized
particles.
3.4. Virus capture by Con A-immobilized nanoparticles
HIV-1 is a spherical RNA virus with a diameter of 100 nm
and possesses an envelope containing the glycoprotein gp120.
Con A recognizes the gp120 on the HIV-1 surface, in particu-
lar the mannose residues of the oligosaccharide chains [77]. It
was reported that the HIV-1 envelope glycoprotein could be
purified by Con Aeagarose affinity chromatography [78].
Thus, it is possible that gp120 and HIV-1 particles can be ef-
fectively captured by these lectins, if they are ideally immobi-
lized onto certain materials such as micro/nanoparticles.
To investigate the capability of virus capture by Con A-im-
mobilized PMAA nanoparticles (Con A-NP), Con A-NP of
different sizes were mixed with an HIV-1 suspension in me-
dium. The amount of captured HIV-1 was determined by theresidual gp120 antigen level and the viral infectivity in the su-
pernatants after centrifugation. Fig. 6 shows the capture effi-
ciency of inactivated HIV-1 by Con A-NP of different sizes
[76]. A dose-dependent increase of capture efficiency was ob-
served with increasing concentrations of Con A. However, no
significant differences in capture efficiency were found among
the different particle sizes. This result indicates that capture ef-
ficiency of Con A-NP depends on the amount of immobilized
Con A. The size of the Con A-NP was increased to about
200 nm when the HIV-1 particles and gp120 antigens were
captured, and slight aggregation was observed (data not
shown). This aggregation is attributed to the crosslinking of
Con A-NP by the HIV-1 particles and gp120 antigens [53,79].
Con A-NP of different sizes could equally capture inacti-
vated HIV-1. It was reported that enzymes immobilized onto
micro/nanospheres had a lower apparent affinity for their sub-
strates than the free enzyme [80,81]. This phenomenon may be
attributed to the steric hindrance of the active site by the nano-
particles, the loss of enzyme flexibility necessary for substrate
binding, or denaturation of the immobilized enzyme by cou-
pling reactions. Thus, the possibility exists that a loss of
6735T. Akagi et al. / Polymer 48 (2007) 6729e6747binding activity of Con A immobilized onto the nanoparticles
may be caused by steric hindrance of the mannose binding
sites, or denaturation. However, Con A-NP could efficiently
capture inactivated HIV-1 and the capture efficiency for inac-
tivated HIV-1 was similar in all cases tested. These results sug-
gest that the size of the nanoparticles (300e1200 nm) does not
significantly influence the mannose binding activity of Con A.
3.5. Development of an anti-HIV-1 vaccine using HIV-1-
capturing nanoparticles
The development of a prophylactic/therapeutic HIV-1 vac-
cine based on recombinant proteins is needed for the control
of theworldwide spread of the acquired immune deficiency syn-
drome (AIDS) epidemic. Subunit protein and peptide vaccines
are generally very safewithwell-defined components. However,
these antigens are often poorly immunogenic and thus require
the use of adjuvants to induce adequate immunity [82,83].
Particulate adjuvants (e.g. micro/nanoparticles, emulsions,
ISCOMS, liposomes, virosomes, and virus-like particles)
have been widely investigated as HIV-1 vaccine delivery sys-
tems [84]. The adjuvant effect of the micro/nanoparticles ap-
pears to be largely a consequence of their uptake into
antigen-presenting cells (APC). More importantly, particulate
antigens have been shown to be more efficient than soluble an-
tigens for the induction of immune responses [85,86]. There
are several factors that can affect the immune response in-
duced by immunization with particulate antigens. Among
them are the particle sizes, the chemical structure of the parti-
cles, their surface hydrophilicity, zeta potential, and adjuvants
used within the formulations.
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Fig. 6. Effect of the particle size on the capture efficiency of HIV-1 with Con
A-NP. Various concentrations of Con A-NP of different sizes and inactivated
HIV-1 suspension were mixed, and incubated for 24 h at 4 C. After incuba-
tion, the supernatants were collected and the residual gp120 antigen levels
were determined by ELISA. The capture efficiency for HIV-1 with Con A-
NP was calculated by: (residual gp120 antigen/initial concentration of
gp120) 100. Data from Ref. [76].To that end, we focused on the development of an HIV-1
vaccine using HIV-1-capturing Con A-NP (HIV-NP) [76,87e
90]. Various strategies for immunization with HIV-NP
(350 nm) were undertaken to induce an HIV-1-specific IgA re-
sponse in the mouse genital tract. HIV-NP were administered
intravaginally, orally, intranasally or intraperitoneally to these
mice. As shown in Fig. 7, intranasal immunization with HIV-
NP was more effective as compared with the other immuniza-
tion routes in terms of a vaginal IgA response [88]. In addition,
vaginal washes from intranasally immunized mice were capa-
ble of neutralizing HIV-1IIIB. Thus, the application of HIV-NP
is a practical approach to promote HIV-1-specific IgA re-
sponse from the mouse vaginal mucosa, and the intranasal
route appears to be an effective immunization strategy in
this animal model.
To examine whether these results would translate to a non-
human primate model and whether the generated immunity
was protective, we used the rhesus macaque/SHIV system.
Three macaques were intranasally immunized with Con A-
NP or inactivated SHIV KU-2-capturing nanoparticles
(SHIV-NP). Moreover, to determine whether the intranasal im-
munization would have a protective effect against an intrava-
ginal challenge with pathogenic SHIV KU-2, all of the
macaques were vaginally inoculated with SHIV KU-2. Intra-
nasal immunization with SHIV-NS could effectively induce
HIV-1-specific antibody responses. After the intravaginal chal-
lenge, viral RNA loads in the plasma were much lower in the
SHIV-NP-immunized macaque than in the control macaque
(data not shown) [90]. Thus, SHIV-NP-immunized macaques
exhibited partial protection against vaginal and systemic chal-
lenges with SHIV KU-2. These results may be helpful for the
development of a vaccine against AIDS.
4. Preparation of biodegradable nanoparticles based
on amphiphilic poly(amino acid)
Numerous investigators have shown that the biological dis-
tribution of drugs, proteins and DNA can be modified, both at
the cellular and organ levels, using micro/nanoparticle deliv-
ery systems. Recently, many studies have focused on self-
assembled biodegradable nanoparticles for biomedical and
pharmaceutical applications. In particular, poly(amino acid)s
have received considerable attention for their medical applica-
tions as potential polymeric drug carriers. Several amphiphilic
block and graft copolymers based on poly(amino acid) have
been employed such as poly(L-glutamic acid) [91], poly(L-as-
partic acid) [11,92], poly(L-lysine) [93,94], poly(L-arginine)
[95], poly(L-asparagine) [96], and poly(g-glutamic acid)
[97e99] as hydrophilic segments, and poly(b-benzyl-L-aspar-
tate) [100], poly(g-benzyl-L-glutamate) [101], and poly(L-his-
tidine) [102] as hydrophobic segments. Amphiphilic
copolymers based on poly(amino acid) form micelles through
self-association in water. The formed micelles can act as hy-
drophobic drug carriers such as for the anticancer agent adria-
mycin. Enhanced tumor accumulation, long blood circulation
times, and effective treatment of solid tumors of those drug-
load micelles have been reported [100].
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from Ref. [88].We have studied the synthesis and clinical applications of
core-corona polymeric nanoparticles composed of hydropho-
bic polystyrene and hydrophilic macromonomers. However,
both biodegradability and biocompatibility are required for
medical use. Therefore, the development of biodegradable
nanoparticles is indispensable for these applications. To this
end, we prepared novel biodegradable nanoparticles com-
posed of hydrophobically modified poly(g-glutamic acid)
(g-PGA).
4.1. Synthesis of g-PGA hydrophobic derivatives
g-PGA is a bacterially produced, water-soluble polyam-
ide, which is the object of current interest because of its nat-
ural origin and biodegradability [103e105]. This polymer is
different from proteins in that peptide linkages are formed
between the a-amino and the g-carboxylic acid groups. It
is a high molecular weight polypeptide composed of g-linked
glutamic acid units, and its a-carboxylate side chains can be
chemically modified. We also developed a modified method
to prepare g-PGA as a drug delivery carrier [106], a tissue
engineering material [107], and a thermosensitive polymer
[108].
g-PGA hydrophobic derivatives (g-hPGA) were synthe-
sized by the covalent attachment of L-phenylalanine ethyl-
ester (L-PAE) to g-PGA via an amide bond (Fig. 8).
g-PGA is a hydrophilic segment which has biodegradable
components containing carboxyl functional groups at the side
chains. L-PAE is a hydrophobic segment and was chosen as
a nontoxic amino acid. g-PGA (number-average molecular
weight, Mn¼ 380,000, D/L ratio¼ 6:4, pKa¼ 2.3) was hydro-
phobically modified by L-PAE in the presence of WSC in50 mM NaHCO3 (pH 8.5) for 24 h at room temperature.
The resulting solutions were then dialyzed against distilled
water using cellulose membrane tubing (50,000 molecular
weight cut off) for 72 h at room temperature. The dialyzed
solutions were then freeze dried. The degree of grafting of
L-PAE was determined by 1H NMR using integrals of the
methylene peaks of g-PGA and the phenyl group peaks of
phenylalanine (Fig. 9). Graft copolymers with different de-
grees of L-PAE grafting were prepared by changing the molar
ratio of the glutamic acid units of g-PGA to WSC (Table 1).
WSC reacts with the carboxyl groups of g-PGA to form an
active ester intermediate, which then reacts with a primary
amine group from L-PAE to form an amide bond. The degree
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Fig. 8. Chemical structure of g-PGA and synthesis scheme for g-PGA-graft-L-
PAE (g-PGA hydrophobic derivatives).
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Fig. 9. 1H NMR spectra of g-PGA (a), L-PAE (b), and g-PGA-graft-L-PAE-53 (c) at 80 C in DMSO-d6.of L-PAE grafting can be easily controlled by altering the
amount of WSC [21,22].
4.2. Preparation of g-hPGA nanoparticles
Amphiphilic block/graft copolymers can self-aggregate in
aqueous solution due to their intra- and/or intermolecular hy-
drophobic interactions [109,110]. Therefore, g-hPGA nano-
particles composed of g-PGA-graft-L-PAE were prepared
by a precipitation and dialysis method. g-PGA-graft-L-PAE
(10 mg) was dissolved in 1 ml of DMSO, followed by the ad-
dition of saline at the same volume as the solvent to yield
a translucent solution. The solutions were then dialyzed
against distilled water using cellulose membrane tubing
(50,000 molecular weight cut off) to form the nanoparticles
Table 1
Synthesis of g-PGA-graft-L-PAE copolymers
Run g-PGA
(unit mmol)
L-PAE
(mmol)
WSC
(mmol)
Yield (%) Grafting
degreea (%)
1 4.7 4.7 0.5 50 10
2 4.7 4.7 1.2 50 18
3 4.7 4.7 2.4 58 23
4 4.7 4.7 3.5 52 36
5 4.7 4.7 3.8 56 43
6 4.7 4.7 4.2 59 49
7 4.7 4.7 4.7 64 53
8 4.7 4.7 5.2 61 61
9 4.7 4.7 9.4 65 64
a Grafting degree of L-PAE was measured by 1H NMR.and to remove the organic solvents for 72 h at room temper-
ature. The size distribution and surface charge of the
g-hPGA nanoparticles in aqueous media were then measured
by dynamic light scattering (DLS) and zeta potential
measurements.
g-PGA-graft-L-PAE could form nanoparticles due to its
amphiphilic characteristics. Fig. 10 shows a representative
size distribution (a) and zeta potential plot (b) of nanoparticles
prepared from g-PGA-graft-L-PAE with a 53% grafting degree
(g-PGA-NP-53) in PBS [111]. The mean diameter and zeta
potential of g-hPGA nanoparticles of various L-PAE grafting
degrees are summarized in Table 2. These nanoparticles could
be prepared from g-PGA-graft-L-PAE with 43e61% L-PAE
grafting. The size of the g-hPGA nanoparticles decreased
with an increasing degree of L-PAE grafting [111]. This in-
creased grafting may enhance the hydrophobic interactions be-
tween the L-PAE groups attached to the g-PGA backbone,
resulting in an increased stability of the hydrophobic cores.
Thus, the size of the g-hPGA nanoparticles can be controlled
by the degree of L-PAE grafting. However, g-PGA-graft-L-
PAE with a low L-PAE grafting of 10e36% could not form
nanoparticles due to the weak interactions between the
L-PAE groups attached to the g-PGA backbone. These graft
copolymers were dissolved in water. The g-hPGA nanoparticles
showed a highly negative zeta potential in PBS. However, the
zeta potential seemed to be independent of the grafting degree
(Table 2) [111]. Fig. 11 shows scanning electron microscope
(SEM) images of the g-PGA-NP-53. These nanoparticles
were spherical in shape and the sizes of the nanoparticles
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Fig. 10. Particle size (a) and surface charge (b) of g-hPGA nanoparticles (g-PGA-NP-53) measured by DLS and zeta potential measurements. Data from
Ref. [111].observed by SEM were in agreement with the results of the
DLS measurements.
4.3. Characterization of g-hPGA nanoparticles
Hydrophobic domains in the g-hPGA nanoparticles were
detected with the Coomassie Brilliant Blue (CBB) G-250
dye. CBB is highly soluble in water, but also possesses
a marked hydrophobic character, mainly due to the presence
of six aromatic rings. This molecule may thus participate in
strong hydrophobic interactions. Moreover, its wavelength of
maximum absorption is shifted from 584 nm in polar media
to 618 nm in nonpolar media [112]. Thus, in this
Table 2
Particle size and zeta potential of g-hPGA nanoparticles composed of various
L-PAE grafting degrees
Run Grafting
degree (%)
Particle sizea
(nm)
C.V.b (%) Zeta potentiala
(mV)
1 10 No particles e e
2 18 No particles e e
3 23 No particles e e
4 36 No particles e e
5 43 305 26.3 24.5
6 49 271 26.2 23.8
7 53 200 24.1 26.3
8 61 152 20.1 24.4
9 64 Aggregation e e
Data from Ref. [111].
a Particle size and zeta potential of g-hPGA nanoparticles were measured in
PBS by a Zetasizer nano ZS.
b C.V. (coefficient of variation)¼ SD (standard deviation)/mean diameter.experiment, CBB was used as a probe of its microenviron-
ment polarity.
The absorption spectra of CBB in nanoparticle (g-PGA-
NP-53) solutions of different concentrations are shown in
Fig. 12. The maximum absorption peak of CBB was shifted
towards higher wavelengths when the nanoparticles’ concen-
tration was increased. However, for the unmodified g-PGA
or L-PAE monomer (dissolved in PBS) alone, the absorbance
remained constant (data not shown). These results suggest
that the maximum absorption change in the case of g-hPGA
nanoparticles can be attributed to the presence of hydrophobic
domains. These hydrophobic domains probably result from the
intra- or intermolecular associations of L-PAE attached to
Fig. 11. SEM images of g-hPGA nanoparticles (g-PGA-NP-53).
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Fig. 12. Absorption spectra of CBB (0.05 mM) in PBS with various concentrations of g-hPGA nanoparticles (g-PGA-NP-53).g-PGA. The specific self-assembly behavior of g-PGA-graft-L-
PAE in aqueous solution is due to multiple phenyl group stack-
ing [111,113e115].
To investigate the distribution of carboxyl groups on the sur-
face, the g-hPGA nanoparticles were suspended in buffers of
varying pH values (pH 3e11), and the zeta potential was then
determined. The zeta potential did not change at pH from 4 to
8. However, it increased with a decrease in pH from 3 to 4 and
reached to 7 mVat pH 3.5 (Fig. 13). The nanoparticles below
pH 3.5 formed aggregates. This change in the zeta potential was
due to the ionization of the carboxyl groups of g-PGA located
near the surface [113]. These results suggest that the structure
of the nanoparticles is a coreeshell type, with an L-PAE core
and an outer g-PGA cortex. The g-hPGA nanoparticles were
stably dispersed in PBS for a month. Furthermore, freeze-dried
samples could be re-dispersed in aqueous solution and repro-
duced the same particle size. Moreover, in vitro cytotoxicity
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Fig. 13. Changes in the zeta potential of g-hPGA nanoparticles (g-PGA-NP-
53) as a function of pH. The measurements of the zeta potential were carried
out in 50 mM buffer at various pH values (pH 3e11, pH 3e5: citrate; pH 6e8:
phosphate citrate; pH 9e11: carbonate).testing showed that the present nanoparticles did not induce
any cytotoxicity against HL-60 cells [113].
5. Biodegradability of g-hPGA nanoparticles
The biodegradation rate of nanoparticles and the release ki-
netics of loaded drugs can be controlled by their composition
ratio, and by the molecular weight of the polymer and graft or
block copolymers [116e119]. Therefore, a study of the degra-
dation kinetics is important for biodegradable polymers. How-
ever, the degradation properties of nanoparticles prepared
from amphiphilic polymers have been studied by only a few
research groups [120,121]. It has also been reported that the
rate of enzymatic degradation of a polypeptide and its deriva-
tives is dependent upon the hydrophobicity, D/L-isomer com-
position, conformation (a-helix and random coil), and
modifications of the side chains of the polymer [122e125].
5.1. Hydrolytic degradation behavior of g-hPGA
nanoparticles
The biodegradability of g-PGA and g-hPGA nanoparticles
was estimated from the decrease in their molecular weight fol-
lowing hydrolytic degradation. The hydrolysis of g-PGA has
been investigated in detail. Fan et al. investigated the hydroly-
sis of g-PGA in different pH solutions [126]. When g-PGA
was incubated in a neutral buffer at 37 C, only approximately
10% of the polymer had been hydrolyzed after 60 days. Goto
et al. also reported the effects of temperature on the hydrolysis
of g-PGA [127]. The rate of hydrolysis could be accelerated
with an increase in the temperature.
The hydrolysis of g-PGA, g-PGA-graft-L-PAE-10, and
g-PGA-NP-53 was carried out at 80 C in phosphate buffer
(pH 7.4 and 12) as an acceleration test. Three samples with
different hydrophobicities were used to study the effect of
the hydrophobicity of the polymer on the hydrolytic degrada-
tion behavior. After 6, 12, 24, and 48 h, the degraded samples
of g-PGA and its derivatives were analyzed using GPC.
Fig. 14 shows the increase in the degradation ratio versus
the hydrolysis time at pH 7.4 (a) and 12 (b) [111,115]. An in-
crease in the hydrolysis ratio was observed for the three
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Fig. 14. Degradation of g-PGA, g-PGA-graft-L-PAE-10 and g-hPGA nanoparticles (g-PGA-NP-53) by hydrolysis for different incubation periods in pH 7.4 (phos-
phate) (a), pH 12 (Na2HPO4/NaOH) (b), and GPC traces of g-PGAwith different standing periods in pH 7.4 at 80
C (c). The degradation ratio was calculated as:
½ðMn0 Mnt Þ=Mn0   100, where Mn0 and Mnt are the number-averaged molecular weight prior to degradation and the Mn at time ‘‘t’’ of degradation, respectively.
The results for g-PGA are presented as means SD (n¼ 3). Data from Refs. [111,115].polymers at both pH values. The hydrolysis ratios of hydro-
phobically modified g-PGA were much lower than those of
unmodified g-PGA at both pH values. The introduction of
L-PAE groups into g-PGA delayed the polymer hydrolysis.
This could be attributed to the hydrophobicity of g-PGA. It
can be assumed that water molecules cannot easily attack
the g-PGA-NP-53 in comparison to g-PGA. The hydrolysis
of the polymer was thus limited by the rate of penetration
and diffusion of water into the core of the nanoparticles
[128]. Moreover, the polymer hydrolysis ratio was higher at
pH 12 as compared to pH 7.4. This result suggests that the
pH is an important factor for the degradation of g-PGA and
its derivatives. Kubota et al. reported the alkaline hydrolysis
of g-PGA [129] and observed that the hydrolysis of g-PGA
was accelerated by the addition of NaOH. The introduction
of L-PAE into g-PGA also influenced the hydrolysis ratio of
the polymer. Consequently, the hydrolysis ratio of g-PGA-
NP-53 was lower than that of g-PGA.
5.2. Enzymatic degradation of g-hPGA nanoparticles
The enzymatic degradation of g-PGA nanoparticles was
evaluated with g-glutamyl transpeptidase (g-GTP). g-GTP
catalyzes the transfer of the g-glutamyl moiety of g-glutamyl
compounds, such as glutathione, to various amino acids and
peptide acceptors. It was observed that g-PGAwas hydrolyzed
to glutamic acids by g-GTP [130].
The enzymatic degradation of g-PGA, g-PGA-NP-53,
g-PGA-NP-74, and poly-L-glutamic acid (a-PGA) was examined
using g-GTP. Four samples of the polymer were used to study
the effects of the degree of L-PAE grafting on the degradation or
disruption of the nanoparticles with g-PGA as the main chain.
After 2, 4, 6, 12, 24, and 48 h, the degraded samples of the poly-
mer were analyzed by GPC. Fig. 15 shows the time dependence
of the increased degradation ratio during degradation with
g-GTP [111,115]. The degradation ratio of g-PGA and g-PGAderivatives was found to be dependent on the degradation time.
In contrast, a-PGAwas not degraded by g-GTP. g-PGA and g-
PGA-NP-53 did not show any significant differences in their de-
gradability after 48 h of incubation with g-GTP. However, the
degradation of g-PGA-NP-74 was slower than that of g-PGA.
The increased grafting degree of L-PAE may have enhanced
the hydrophobic interactions between the L-PAE groups attached
to the g-PGA backbone, thus resulting in an increased packing
and stability of the hydrophobic core. It is hypothesized that
the core of the nanoparticle was formed not only by L-PAE, but
also by a g-PGA from the main chain because of the graft copol-
ymer with a short hydrophobic domain [111]. Therefore, it is
suggested that g-PGA incorporated into the core is resistant to
degradation by g-GTP.
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Fig. 15. Degradation of g-PGA, g-hPGA nanoparticles (g-PGA-NP-53, -73)
and a-PGA by g-GTP for different incubation periods at 37 C. The degrada-
tion ratio was calculated as: ½ðMn0 Mnt Þ=Mn0   100, the results for g-PGA
are presented as means SD (n¼ 3). Data from Ref. [115].
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gillus sojae (protease), cathepsin B (CB), and lipase] were
selected for the enzymatic degradation of g-PGA, g-PGA-
NP-53, and a-PGA. Three samples of the polymer were used
to study the cleavage of the amide bond between the a-carbox-
ylate side chain of g-PGA and L-PAE. PE is a serine protease
complex derived from bacteria. CB belongs to the family of
cysteine proteases and has been found in various cells. It is in-
volved in the intracellular digestion of extracellular proteins
taken in by endocytosis.
The enzymatic degradation studies were carried out in vitro
at 37 C in phosphate buffer containing each enzyme. Fig. 16
shows the degradation ratio after enzymatic degradation for 0,
2, 4, 6, 12, and 24 h with PE (a), protease (b), CB (c), andlipase (d) [115]. a-PGAwas degraded rapidly by PE, protease
and CB, but slowly by lipase. In contrast, g-PGA was only
affected by lipase. It has been reported that g-PGA was not
easily degraded by proteases, such as papain, pepsin, or bro-
melain [105,131]. In the case of g-PGA-NP-53, a decrease
in the molecular weight of g-PGA-graft-L-PAE was observed
with all enzymes tested. There are two possible cleavage sites
on g-PGA-graft-L-PAE. One is the amide bond of the g-PGA
composed of g-linked glutamic acids, and the other is the am-
ide bond between the a-carboxylate side chains of g-PGA and
L-PAE. When L-PAE introduced into g-PGA is cleaved com-
pletely, the molecular weight decreases by about 50%. From
Fig. 16, it can be seen that the cleavage of g-PGA occurred
with lipase, and that the cleavage of the amide bond between(d)  Lipase
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Fig. 16. Enzymatic degradation of g-PGA, g-hPGA nanoparticles (g-PGA-NP-53) and a-PGA by Pronase E (PE) (a), protease from A. sojae (protease) (b),
cathepsin B (CB) (c), and lipase (d) for different incubation periods at 37 C. The degradation ratio was calculated as: ½ðMn0 Mnt Þ=Mn0   100. Data from
Ref. [115].
6742 T. Akagi et al. / Polymer 48 (2007) 6729e6747the a-carboxylate side chains of g-PGA and L-PAE occurred
using PE, protease, CB, and lipase.
Fig. 17 shows the change in the particle size of g-PGA-NP-
53 as the degradation progressed with PE [115]. The size of the
nanoparticles increased slightly from 190 to 257 nm during the
first 1 h, and then gradually decreased with time. These results
suggest that the enzymatic cleavage of L-PAE may lead to
a lighter packing density of the core of the nanoparticles.
Therefore, the increase in particle size at the initial degradation
may be attributed to an increase in the swelling capacity due to
the cleavage of L-PAE in the core of the nanoparticles. On the
other hand, the hydrophobic interactions of L-PAE attached to
g-PGAwere significantly reduced upon increasing the degrada-
tion time, since it is not sufficient to form any nanoparticles.
Therefore, the decrease in the particle size with further
degradation probably occurs upon the dissociation of g-PGA-
graft-L-PAE from the nanoparticles, or via the aggregation of
g-PGA-graft-L-PAE detached from the nanoparticles. During
the degradation process, the size of the g-PGA nanoparticles
changed significantly. It has also been reported that the hydro-
lytic degradation of amphiphilic block copolymer micelles
affects their particle size and morphologies [132].
6. Preparation and characterization of protein-loaded
g-hPGA nanoparticles
Biodegradable polymeric nanoparticles are generally for-
mulated using the emulsion solvent evaporation method. Sur-
factants are often used to stabilize the nanoparticles in aqueous
solution in order to prevent the aggregation and/or precipita-
tion of water insoluble polymers, such as PLA and PCL
[133]. However, adequate removal of the surfactant remains
a problem and surfactant molecules are sometimes harmful
in biomedical applications. Moreover, the water-in-oil-in-
water (w/o/w) double emulsion process is typically used to
load proteins into nanoparticles. It has a disadvantage in that
these solvents have a denaturing effect on the proteins
[134,135]. In addition, during the degradation process, a low
pH is generated inside the biodegradable nanoparticles. In
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Fig. 17. Changes in the size of g-hPGA nanoparticles (g-PGA-NP-53) as
a function of the degradation time with Pronase E (PE). The size distribution
of the g-hPGA nanoparticles was measured in PBS by DLS. Data from
Ref. [115].this method, the entrapped protein may be denatured, aggre-
gated and chemically degraded [136,137]. Therefore, a novel
type of nanoparticle needs to be developed.
6.1. Encapsulation of proteins into g-hPGA
nanoparticles
Protein-encapsulated g-hPGA nanoparticles were prepared
in order to study their potential applications as protein carriers.
To prepare the protein-encapsulated g-hPGA nanoparticles,
0.25e4 mg of protein (thyroglobulin, catalase, Con A, bovine
serum albumin (BSA), ovalbumin (OVA), peroxidase, b-lacto-
globulin, myoglobin, lysozyme, a-lactalbumin, and cyto-
chrome c) was dissolved in 1 ml of saline and 1 ml of
g-PGA-graft-L-PAE-53 (10 mg/ml in DMSO) was added to the
protein solution. The resulting solution was centrifuged and
repeatedly rinsed. The protein loading content was then mea-
sured by Lowry method [113,114].
The encapsulation of proteins of various molecular weights
and isoelectric points into the nanoparticles was successfully
achieved. The results of the encapsulation of protein into the
nanoparticles are summarized in Table 3 [114]. All proteins
used in this experiment were successfully encapsulated into
the nanoparticles. The encapsulation efficiency was found to
be in the range of 30e60% for most samples. The amount
of protein encapsulated into the nanoparticles was increased
upon increasing the initial feeding amount of protein
(Fig. 18) [114]. For all samples tested, it was observed that
the encapsulation efficiency for a given protein was not mark-
edly influenced by the physical properties of that protein.
Wang et al. reported that nanoparticles prepared from amphi-
philic poly-L-lysine were able to encapsulate hydrophilic
dextran [93].
From the DLS measurements, the mean diameter of the
unloaded g-hPGA nanoparticles was 180 nm with a monodis-
persed size distribution. The particle size of the nanoparticles
was increased when various proteins were encapsulated (Table
3). These results might be due to an increase in the swelling
capacity of the nanoparticles due to the hydrophilic properties
of the protein [113]. Na et al. reported that the introduction
of vitamin H into hydrophobically modified pullulan, pullulan
acetate, enhanced the formation of swelling hydrogel nanopar-
ticles due to the hydrophilicity of vitamin H [138]. In the
preparation of lysozyme-encapsulated nanoparticles, a large
amount of aggregation was found. This result can be attributed
to the strong electrostatic interaction between lysozyme
and the nanoparticles at the time of particle formation.
These interactions may disturb the stable formation of inner
cores and thus they could not form monodispersed
nanoparticles.
6.2. Characterization of protein-encapsulated g-hPGA
nanoparticles
To study the protein release behavior, OVA-encapsulated
g-hPGA nanoparticles were suspended in buffers of varying
pH values and the OVA release was then determined in vitro.
6743T. Akagi et al. / Polymer 48 (2007) 6729e6747Table 3
Entrapment efficiency, particle size and zeta potential of protein-encapsulated g-hPGA nanoparticles
Protein Molecular
weight 103 (Mw)
Isoelectric
point (pI )
Entrapment
efficiencya (wt.%)
Loading contentb
(mg/NP 1 mg)
Particle sizec (nm) Polydispersity Zeta potentialc (mV)
Thyroglobulin 670 4.5 52.4 104.9 281 0.29 20.5 2.6
Catalase 232 5.5 60.0 120.1 320 0.26 20.9 3.6
Concanavalin A 104 5.0 51.9 103.8 340 0.26 20.0 5.1
Bovine serum albumin 69 4.9 58.5 116.9 289 0.27 20.9 5.3
Ovalbumin 45 4.6 45.0 90.0 256 0.29 21.6 2.4
Peroxidase 44 7.5 25.3 50.5 202 0.16 23.9 4.4
b-Lactoglobulin 18 5.2 38.6 77.2 233 0.21 23.4 1.9
Myoglobin 17.5 7.3 44.6 89.2 212 0.22 24.0 4.4
Lysozyme 14.5 11.0 31.3 62.6 >3000 1.00 15.1 7.0
a-Lactalbumin 14.0 5.0 28.2 56.3 198 0.22 24.8 4.1
Cytochrome c 12.5 10.2 43.8 87.6 353 0.26 17.0 6.4
g-hPGA nanoparticles 180 0.12 23.8 2.4
Data from Ref. [114].
a g-PGA-graft-L-PAE-53 copolymers and each proteins were mixed to a final concentration of 5 mg/ml and 1 mg/ml. The entrapment efficiency was measured as
(total encapsulated protein weight/initial feeding amount of protein weight) 100.
b The amount of protein loading into g-hPGA nanoparticles was calculated by loaded protein weight (mg)/nanoparticles (NP) weight (1 mg).
c Particle size and zeta potential of g-hPGA nanoparticles were measured in PBS by a Zetasizer nano ZS.The release of OVA from nanoparticles with an OVA content
of 43 mg/NP 1 mg was performed at 37 C. OVA encapsulated
into the nanoparticles was not released (less than 10%) over
the pH range of 4e8, even after 10 days (data not shown)
[113]. These results suggest that the g-PGA backbone com-
posed of g-linked glutamic acid and the amide bond between
the a-carboxylate side chains of g-PGA and L-PAE is not de-
graded under these experimental conditions. It is expected that
protein-encapsulated g-hPGA nanoparticles can release pro-
tein in the cell or in vivo upon enzymatic digestion.
The absence or slow release of OVA from the nanoparticles
can be explained as a consequence of the interaction between
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Fig. 18. Effects of the protein concentration on the amount of protein encap-
sulated into g-hPGA nanoparticles (g-PGA-NP-53). g-PGA-graft-L-PAE (in
DMSO) and protein solutions were mixed to a final copolymer concentration
of 5 mg/ml. The amount of protein encapsulated into the nanoparticles was
calculated as the loaded protein weight (mg)/nanoparticle weight (1 mg).
Data from Ref. [114].OVA and g-PGA-graft-L-PAE. In the case of peptide encapsu-
lation with different hydrophobicities, the peptide with the
higher hydrophobicity showed a higher encapsulation effi-
ciency (data not shown). Therefore, the interaction between
OVA and the nanoparticles may be due to the hydrophobic in-
teractions between the hydrophobic regions of OVA and the
hydrophobic L-PAE groups [114]. The inner structures of the
nanoparticles are likely to retain the flexibility of the protein
encapsulated into the nanoparticles. In the case of nanopar-
ticles prepared from amphiphilic diblock PLAePEG copoly-
mer nanoparticles, the hydrophobic interactions between the
hydrophobic regions of the protein and the hydrophobic
PLA blocks were observed [139].
Since freeze drying is a convenient technique for nanopar-
ticle storage, the effects of freeze drying on the size of the
g-hPGA nanoparticles and the OVA-encapsulated nanoparticles
were studied. After freeze drying, these nanoparticles were
easily re-dispersed in water, and their particle size showed
no change as compared to before freeze drying (data not
shown). The total amount of OVA leaked from the lyophilized
nanoparticles was less than 5% of the total OVA loaded. These
results indicate that the g-PGA nanoparticles and OVA-encap-
sulated nanoparticles have high stability for the freeze-drying
process [113].
6.3. Surface immobilization of protein onto g-hPGA
nanoparticles
Protein-loaded g-PGA nanoparticles could be prepared by
the surface immobilization method. Various proteins were co-
valently immobilized onto the nanoparticles by amide bonds
between the carboxyl groups on the surface of the g-hPGA
nanoparticles and the protein amide groups. The results of
the entrapment of various proteins onto the nanoparticles
are shown in Fig. 19 [114]. The amount of protein immobi-
lized onto the nanoparticles showed different trends at vari-
ous molecular weights and isoelectric points of the protein.
6744 T. Akagi et al. / Polymer 48 (2007) 6729e6747At higher molecular weights, the amount of protein cova-
lently immobilized was larger at a lower molecular weight.
On the other hand, lysozyme and cytochrome c were ad-
sorbed with high yields. Positively charged proteins could
be adsorbed onto negatively charged nanoparticles by elec-
trostatic interactions. It is known that protein loading into
micro/nanoparticles is influenced by both electrostatic inter-
actions and other mechanisms such as hydrophobic interac-
tions and structural accommodation of the polymer and
biomolecule [140]. Except for lysozyme, the entrapment
efficiency onto the surface of nanoparticles using WSC was
only about 1e10%. These results demonstrate that the
entrapment efficiency for a given protein is significantly
dependent on the conjugation method.
The surface area of nanoparticles per milligram was
200 cm2 for 200 nm-sized nanoparticles. In the case of OVA
surface immobilization, the theoretical amount of OVA immo-
bilized onto the surface was about 80 mg/NP 1 mg at maxi-
mum. On the other hand, the amount of OVA encapsulated
into the nanoparticles was about 150 mg/NP 1 mg (initial
OVA conc. 2 mg/ml). The loading capacity of OVA into the
nanoparticles was higher than the theoretical amount of
OVA immobilized onto the surface [113]. Thus, the interior
space of the nanoparticles has great potential to load proteins.
When compared with the amount of protein loading, the en-
capsulation method appeared to be more effective than the
immobilization method.
6.4. Effect of the conjugation method on catalase activity
The effect of the conjugation method on the enzymatic activ-
ity of catalase-entrapped g-hPGA nanoparticles was also eval-
uated using H2O2. Catalase-entrapped nanoparticles were
prepared by the encapsulation (48 mg/NP 1 mg), covalent im-
mobilization (27 mg/NP 1 mg), and physical adsorption
(13 mg/NP 1 mg) methods. Fig. 20 shows the activity of the
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Fig. 19. Immobilization and adsorption of various proteins onto the surface of
g-hPGA nanoparticles (g-PGA-NP-53). g-hPGA nanoparticles treated (cova-
lent immobilization) or untreated (physical adsorption) with 500 mg/ml of
WSC, nanoparticles and each protein solution were mixed, to final concentra-
tions of 5 mg/ml and 1.75 mg/ml, respectively. The results are presented as
means SD values (n¼ 3). Data from Ref. [114].catalase-entrapped in/onto the nanoparticles [114]. The cata-
lase activity was significantly affected by the conjugation
method. For encapsulation, the catalase activity was higher
than that of the immobilization and adsorption methods. The
catalase covalently immobilized onto the nanoparticles showed
the lowest activity in these conjugation methods. Based on
these results, it is likely that the interactions between the pro-
teins and nanoparticles in the protein-encapsulated nanopar-
ticles were weaker than those of the immobilization and
adsorption methods, and protein flexibility was not impaired
significantly by its encapsulation. The stability of the protein
encapsulated into the nanoparticles may be attributed to the
preparation method of protein-encapsulated nanoparticles.
In this study, protein-encapsulated nanoparticles were pre-
pared by a precipitation and centrifugal washing method. In
the case of protein-encapsulated nanoparticles prepared by
the self-assembly of g-PGA-graft-L-PAE, the encapsulated
protein may be more stable than via the emulsion method. Pro-
teins encapsulated into the g-hPGA nanoparticles appear to be
adequate in terms of the preservation of the protein structure.
Protein stability in nanoparticles is considered to play a signif-
icant role in the induction of adequate immune responses for
vaccines [141,142]. In this experiment, encapsulation was
the optimal method for the conjugation of proteins and
nanoparticles. In fact, immunization of mice with protein
antigen-encapsulated g-hPGA nanoparticles strongly induced
antigen-specific humoral and cellular immunity [143]. This
system provides a novel delivery tool and an efficient antigen
delivery system in the development of protein-based vaccines.
7. Conclusions
Monodispersed polymeric nanoparticles, which consist of
a hydrophobic core and a hydrophilic corona on their surfaces,
were prepared by the free radical dispersion copolymerization
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Fig. 20. Effects of the conjugation method on the activity of catalase. The cat-
alase activities of free catalase (free), catalase-encapsulated (encapsulation),
catalase-immobilized (immobilization), and catalase-adsorbed (adsorption)
g-hPGA nanoparticles (g-PGA-NP-53) were determined spectrophotometri-
cally by the direct measurement of the decrease in the absorbance of hydrogen
peroxide (20 mM) at 240 nm. The results are presented as means SD values
(n¼ 3). Data from Ref. [114].
6745T. Akagi et al. / Polymer 48 (2007) 6729e6747of hydrophobic monomers and hydrophilic macromonomers in
a polar solvent. Core-corona type nanoparticles could be
widely utilized for various technological and biomedical ap-
plications, because of their possible variety of chemical struc-
tures. These nanoparticles were utilized as oral drug carriers
for peptide drugs physically adsorbed onto the nanoparticle
surfaces. Moreover, lectin-immobilized nanoparticles could
efficiently capture HIV-1 particles and have great potential
as a prophylactic vaccine against HIV-1 infection. Based on
these studies, we attempted to develop novel biodegradable
nanoparticles composed of g-hPGA. Protein-entrapped
g-hPGA nanoparticles were prepared in order to study their
potential applications as protein carriers. It is expected that
biodegradable g-hPGA nanoparticles can encapsulate and
immobilize proteins, peptides, plasmid DNA, and drugs.
These multifunctional nanoparticles have great potential as
carriers for biomolecules. These characteristics strongly sug-
gest that g-PGA nanoparticles can be developed as useful vac-
cine carriers for modulated biodistribution, as well as site and/
or cell-specific drug delivery systems. Nanoparticles prepared
by the self-organization of polymers consisting of hydropho-
bic and hydrophilic segments show promise as drug delivery
systems as a result of their controlled- and sustained-release
properties, subcellular size, and biocompatibility with tissue
and cells.
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